MUCOSAL RNA VACCINE: Development of a novel replication-deficient mucosal RNA vaccine protecting against respiratory viral disease of early childhood

• Research unit: EU RFP
• Project number: 02.0287

Key words (English)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Alternative project number (English)

EU project number: QLK2-CT-01722

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Short description (English)

See abstract

Abstract (English)

The aim of the project is the development and the pre-clinical evaluation of a mucosal RNA-based virosomal vaccine against respiratory diseases of the early childhood caused by human parainfluenza virus type 3 and respiratory syncytial virus. Antigens are encoded on a Sendai virus RNA packaged in a nucleocapsid andencapsulated into immunostimulating-reconstituted virosomes. For an excellent safety standard, the nucleocapsid is completely replication-deficient by deletion of the N gene. Antigen combinations are provided by a single vaccine formulation in a modular system. The vaccine will be applied in a one step process and the administration as a nasal spray allows an easy reapplication. This makes the new formulation economic, effective, safe and highly adaptable for vaccination of humans (also of animals) against various infectious diseases.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 02.0287